The trefoil factor 1 (TFF1) protein involved in doxorubicin‑induced apoptosis resistance is upregulated by estrogen in breast cancer cells

Pelden,Sonam; Insawang,Tonkla; Thuwajit,Chanitra; Thuwajit,Peti

doi:10.3892/or.2013.2593

The trefoil factor 1 (TFF1) protein involved in doxorubicin‑induced apoptosis resistance is upregulated by estrogen in breast cancer cells

Authors:
- Sonam Pelden
- Tonkla Insawang
- Chanitra Thuwajit
- Peti Thuwajit
View Affiliations

Affiliations: Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Published online on: July 5, 2013 https://doi.org/10.3892/or.2013.2593
Pages: 1518-1526

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trefoil factor 1 (TFF1) is a small secretory protein expressed in various types of carcinomas including breast cancer. The TFF1 gene contains an estrogen response element and its expression can be regulated by estrogen. Previous reports showed that TFF1 could protect cells from induced apoptosis in vitro. In the present study, the effect of estrogen on the promotion of doxorubicin-induced apoptosis resistance and the role of TFF1 in this process was demonstrated using the MCF-7 breast cancer cell model. Stable knockdown of the TFF1 gene in MCF-7 cells was generated and used to test the sensitivity to doxorubicin treatment compared to mock control cells in the presence or absence of 17β-estradiol. The apoptotic cells were measured by flow cytometry. The results showed that with the stimulation of apoptosis by doxorubicin, 17β-estradiol could suppress this process in mock cells but not in TFF1 knockdown cells. Moreover, using a viable cell counting method, it was shown that the anti-TFF1 antibody could reverse the anti-apoptotic effect of estrogen in mock cells and recombinant TFF1 could recover doxorubicin-induced cell death in TFF1 knockdown cells. This process, however, could not be inhibited by fulvestrant, an estrogen antagonist. An apoptosis protein array experiment reflected the role of the anti-oxidative enzyme catalase in estrogen and TFF1-modulated apoptosis and this was confirmed by enzymatic assay. These phenomena determine the role of TFF1 in estrogen-promoted resistance to apoptosis induced by doxorubicin in MCF-7 breast cancer cells. The TFF1 gene may be a target for enhancing the sensitivity to chemotherapy in breast cancer treatment.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Porter P: ‘Westernizing’ women's risks? Breast cancer in lower-income countries. N Engl J Med. 358:213–216. 2008.
3	Tuttle TM, Rueth NM, Abbott A and Virnig BA: United States trends in the surgical treatment of primary breast cancer. World J Surg. 36:1475–1479. 2012. View Article : Google Scholar : PubMed/NCBI
4	Arslan C, Altundag K and Dizdar O: Emerging drugs in metastatic breast cancer: an update. Expert Opin Emerg Drugs. 16:647–667. 2011. View Article : Google Scholar : PubMed/NCBI
5	Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA and Rugo HS: The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 29:807–819. 2012. View Article : Google Scholar : PubMed/NCBI
6	Jordan VC and O'Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 25:5815–5824. 2007. View Article : Google Scholar : PubMed/NCBI
7	Allegra JC, Lippman ME, Thompson EB and Simon R: An association between steroid hormone receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer. Cancer Res. 38:4299–4304. 1978.
8	Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 17:460–469. 1999.
9	Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T, Delaloge S, Michiels S and Andre F: Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol. 18:1477–1483. 2007. View Article : Google Scholar
10	Pritchard JE, Dillon PM, Conaway MR, Silva CM and Parsons SJ: A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model. Oncology. 83:305–320. 2012. View Article : Google Scholar : PubMed/NCBI
11	Dickson RB and Stancel GM: Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr. 2000:135–145. 2000. View Article : Google Scholar : PubMed/NCBI
12	Lewis-Wambi JS and Jordan VC: Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 11:2062009. View Article : Google Scholar : PubMed/NCBI
13	Haddow A, Watkinson JM, Paterson E and Koller PC: Influence of synthetic oestrogens on advanced malignant disease. Br Med J. 2:393–398. 1944. View Article : Google Scholar : PubMed/NCBI
14	Ward HW: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1:13–14. 1973. View Article : Google Scholar : PubMed/NCBI
15	Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS and Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 97:1746–1759. 2005. View Article : Google Scholar : PubMed/NCBI
16	Gompel A, Somaï S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M and Rostène W: Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 65:593–598. 2000. View Article : Google Scholar : PubMed/NCBI
17	Teixeira C, Reed JC and Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55:3902–3907. 1995.PubMed/NCBI
18	Perillo B, Sasso A, Abbondanza C and Palumbo G: 17β-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol. 20:2890–2901. 2000.
19	Rio MC and Chambon P: The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells. 2:269–274. 1990.PubMed/NCBI
20	Bossenmeyer-Pourié C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C and Rio MC: The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol. 157:761–770. 2002.PubMed/NCBI
21	Buron N, Guery L, Creuzot-Garcher C, Lafontaine PO, Bron A, Rio MC and Solary E: Trefoil factor TFF1-induced protection of conjunctival cells from apoptosis at premitochondrial and postmitochondrial levels. Invest Ophthalmol Vis Sci. 49:3790–3798. 2008. View Article : Google Scholar : PubMed/NCBI
22	Nunez AM, Jakowlev S, Briand JP, Gaire M, Krust A, Rio MC and Chambon P: Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology. 121:1759–1765. 1987. View Article : Google Scholar : PubMed/NCBI
23	Tomasetto C and Rio MC: Pleiotropic effects of Trefoil Factor 1 deficiency. Cell Mol Life Sci. 62:2916–2920. 2005.PubMed/NCBI
24	Ruchaud-Sparagano MH, Westley BR and May FE: The trefoil protein TFF1 is bound to MUC5AC in human gastric mucosa. Cell Mol Life Sci. 61:1946–1954. 2004. View Article : Google Scholar : PubMed/NCBI
25	Madsen J, Nielsen O, Tornøe I, Thim L and Holmskov U: Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem. 55:505–513. 2007. View Article : Google Scholar : PubMed/NCBI
26	Thuwajit P, Chawengrattanachot W, Thuwajit C, Sripa B, May FE, Westley BR, Tepsiri NN, Paupairoj A and Chau-In S: Increased TFF1 trefoil protein expression in Opisthorchis viverrini-associated cholangiocarcinoma is important for invasive promotion. Hepatol Res. 37:295–304. 2007.PubMed/NCBI
27	Prest SJ, May FE and Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 16:592–594. 2002.PubMed/NCBI
28	Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, Washington MK, Kokoye Y, Crowe SE, Zaika A, Correa P, Peek RM Jr and El-Rifai W: Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest. 121:1753–1767. 2011.
29	Gillesby BE and Zacharewski TR: pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat. 56:253–265. 1999. View Article : Google Scholar : PubMed/NCBI
30	Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W and Stamp GW: Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol. 183:30–38. 1997. View Article : Google Scholar
31	Reshkin SJ, Tedone T, Correale M, Mangia A, Casavola V and Paradiso A: Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies. Cell Prolif. 32:107–118. 1999. View Article : Google Scholar : PubMed/NCBI
32	Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK, Mertani HC, Zhu T, Liu D and Lobie PE: Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology. 150:4473–4483. 2009. View Article : Google Scholar : PubMed/NCBI
33	Buache E, Etique N, Alpy F, Stoll I, Muckensturm M, Reina-San-Martin B, Chenard MP, Tomasetto C and Rio MC: Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice. Oncogene. 30:3261–3273. 2011. View Article : Google Scholar : PubMed/NCBI
34	Miller WR: Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol. 118:273–276. 2010. View Article : Google Scholar
35	Zhou L, Yan T, Jiang Y, Di G, Shen Z, Shao Z and Lu J: Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: comparing aromatase inhibitors with tamoxifen. Breast. 20:15–20. 2011. View Article : Google Scholar : PubMed/NCBI
36	Sinha AK: Colorimetric assay of catalase. Anal Biochem. 47:389–394. 1972. View Article : Google Scholar : PubMed/NCBI
37	Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS and Chin KV: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60:4161–4166. 2000.PubMed/NCBI
38	Troester MA, Hoadley KA, Sorlie T, Herbert BS, Borresen-Dale AL, Lonning PE, Shay JW, Kaufmann WK and Perou CM: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 64:4218–4226. 2004. View Article : Google Scholar : PubMed/NCBI
39	Elmore LW, Di X, Dumur C, Holt SE and Gewirtz DA: Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res. 11:2637–2643. 2005. View Article : Google Scholar : PubMed/NCBI
40	Mobley JA and Brueggemeier RW: Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis. 25:3–9. 2004. View Article : Google Scholar : PubMed/NCBI
41	Sastre-Serra J, Valle A, Company MM, Garau I, Oliver J and Roca P: Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med. 48:506–512. 2010. View Article : Google Scholar : PubMed/NCBI
42	O'Sullivan J, Whyte L, Drake J and Tenniswood M: Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ. 10:914–927. 2003. View Article : Google Scholar : PubMed/NCBI
43	Won YS, Lee SJ, Yeo SG and Park DC: Effects of female sex hormones on clusterin expression and paclitaxel resistance in endometrial cancer cell lines. Int J Med Sci. 9:86–92. 2012. View Article : Google Scholar : PubMed/NCBI
44	Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, Doihara H and Miyoshi S: Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci. 102:2038–2042. 2011. View Article : Google Scholar
45	de Vincenzo R, Scambia G, Benedetti Panici P, Bonanno G, Ercoli A, Fattorossi A, Pernisco S, Isola G and Mancuso S: Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells. Ann NY Acad Sci. 784:517–520. 1996.